Literature DB >> 2237945

Stroke in systemic lupus erythematosus.

Y Kitagawa1, F Gotoh, A Koto, H Okayasu.   

Abstract

We investigated the clinical and pathologic characteristics of stroke in 234 patients with systemic lupus erythematosus. Thirteen patients (5.6%) developed cerebrovascular disease. Cerebral infarction was noted in eight, cerebral hemorrhage in two, and subarachnoid hemorrhage in three. In seven (54%) of these 13 patients, stroke occurred less than or equal to 5 years after systemic lupus erythematosus was diagnosed. Among the predisposing risk factors for stroke, hypertension was the most important. Lupus anticoagulant was detected in three (38%) and anticardiolipin antibody in three (43% of seven investigated) of the patients with infarction. Evaluation of the clinical manifestations and autoantibodies indicated that renal involvement and high titers of anti-deoxyribonucleic acid antibody were more frequent in the stroke group than in the non-stroke group. Autopsy studies on six of the patients with stroke revealed small infarcts and hemorrhages in all, but in no case was true angiitis observed. Libman-Sacks endocarditis was found in two of the three patients with infarction. In conclusion, the important contributory factor to the development of stroke in patients with systemic lupus erythematosus is considered to be hypertension mediated by immunologic abnormalities. Antiphospholipid antibodies and Libman-Sacks endocarditis are closely associated with occlusive cerebrovascular disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2237945     DOI: 10.1161/01.str.21.11.1533

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  19 in total

Review 1.  Can estrogens promote hypertension during systemic lupus erythematosus?

Authors:  Marcia Venegas-Pont; Michael J Ryan
Journal:  Steroids       Date:  2010-02-21       Impact factor: 2.668

2.  Multiple brain calcifications in a patient with systemic lupus erythematosus.

Authors:  Carlos A Cañas; Gabriel J Tobón
Journal:  Clin Rheumatol       Date:  2008-05-28       Impact factor: 2.980

3.  Non-atherosclerotic vascular disease in the young.

Authors:  Osvaldo Camilo; Larry B Goldstein
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

Review 4.  Imaging of cardiovascular complications in patients with systemic lupus erythematosus.

Authors:  K Lin; D M Lloyd-Jones; D Li; Y Liu; J Yang; M Markl; J C Carr
Journal:  Lupus       Date:  2015-06-02       Impact factor: 2.911

Review 5.  Systemic lupus erythematosus and antineutrophilic cytoplasmic antibody-associated vasculitis overlap syndrome complicated by subarachnoid hemorrhage: case-based review.

Authors:  Ciril Khorolsky; Andrew Castellano; David Comstock; Nooshin K Brinster; Sein Y See; Bruce F Garner
Journal:  Rheumatol Int       Date:  2018-10-16       Impact factor: 2.631

6.  Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort.

Authors:  L A González; G J Pons-Estel; J Zhang; L M Vilá; J D Reveille; Graciela S Alarcón
Journal:  Lupus       Date:  2009-08       Impact factor: 2.911

7.  Stroke in Patients with Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome.

Authors:  Claudia J. Chaves
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-06

Review 8.  Estrogen in cardiovascular disease during systemic lupus erythematosus.

Authors:  Emily L Gilbert; Michael J Ryan
Journal:  Clin Ther       Date:  2014-09-04       Impact factor: 3.393

9.  Relation of antiphospholipid antibodies to postmortem brain infarcts in older people.

Authors:  Zoe Arvanitakis; Robin L Brey; Jacob H Rand; Julie A Schneider; Ana W Capuano; Lei Yu; Sue E Leurgans; David A Bennett; Steven R Levine
Journal:  Circulation       Date:  2014-10-09       Impact factor: 29.690

10.  Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors.

Authors:  Carlos Borelli Zeller; Simone Appenzeller
Journal:  Curr Cardiol Rev       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.